Lingang New Area Life Blue Bay was successfully selected as one of the 26 characteristic parks built by Shanghai on March 31 this year. The planned area is 17 square kilometers. After expansion, it will reach 45 square kilometers, focusing on biomedicine, high-end medical equipment, and internationally in the 3 major medical service sectors, in 4 primary industry sectors, 12 secondary sub-industries and 33 sub-sectors, precision diagnosis, precision medicine, precision surgery and related health extension services. The introduction of champion companies will create a technology research and development center with global influence, forming a platform for the development of precision medical industry, a hub for innovation and transformation, and a cluster of innovative services. The planned area of the first phase is 4.5 square kilometers, and there will be continuous construction in the second and third phases in the future.
Currently, about 40 companies have settled in the park. Representative companies include: Junshi Biology, Dejian Conghe, Saijin Biology, Baifan Biology, Zhenge Biology, WuXi AppTec, Heyuan Zhizhi, Faith Medicine and other biomedical industries, as well as Weiming Medical, Mumu Robot, High-end medical equipment industry such as Jinshi Robot, Xinghuo Medical, Ensheng Medical, Junxin Technology, and Haoji Technology. Currently, biomedicine is facing great development and great opportunities. The development of Shanghai’s biopharmaceutical industry has the foundation and potential to keep up with the global frontier and achieve international simultaneous development.
In Shanghai, development of several scientific research carriers such as the Protein Center, Live Cell Imaging Platform, and Zhangjiang Pharmaceutical Laboratory have been accelerated. The gathering of biomedical research talent teams has also accelerated. Additionally, Shanghai has many tertiary hospitals and new drug clinical research bases.
From the perspective of industrial layout, the development of Shanghai’s biomedicine has formed a “one core and multiple points” clustering situation with Zhangjiang as the core. From the perspective of leading companies, the world’s leading pharmaceutical and equipment multinational companies are vying to establish regional headquarters, R&D and production centers in Shanghai, and five biomedical companies have been listed on the Science and Technology Innovation Board. From the perspective of industry trends, Shanghai’s biomedical industry has experienced rapid economic growth. In 2019, the growth rate of its subdivisions such as biological products, medical devices, and chemical preparations exceeded 10%.
According to the “14th Five-Year” development plan, Lingang Blue Bay Park will have an annual output value of 100 billion yuan. The total investment of the park will reach 100 billion yuan, and the comprehensive property space of the park will reach 100 billion yuan. The Park has more than 1,000 high-end innovative talents, and the park has cultivated enterprises with a market value of 100 billion yuan, forming an important development node for the Lingang Special Area. The goal is to strengthen the agglomeration of resource elements, promote the integration of the innovation chain and the industrial chain; plan from a high starting point to create a biomedical cluster area, and accelerate the implementation of innovative R&D and industrialization.